Browse
related articles
France's Carmat to test artificial heart in Saudi Arabia
- Saudi Arabia: 9 hours, 45 minutes ago
French biomedical firm Carmat has announced it has received the approval from four international cardiac surgery centres to proceed with the first human implantations of its artificial heart in four countries including Saudi Arabia, Reuters has reported. "The patient selection process and the training of the clinical teams are ongoing in these four countries... Implantations could start shortly following the completion of the training," Carmat said. Developed by a team of engineers from Airbus parent company EADS, the Carmat devices, expected to cost €150,000 ($193,600) each, mimic heart muscle contractions with two micro pumps, one for each ventricle or heart chamber.
Related Content
Article Options
Disclaimer »
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AMEinfo.com Web site does not constitute advice or a recommendation by AME Info FZ LLC / 4C and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AMEinfo.com Web site.
AME Info FZ LLC / 4C can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AMEinfo.com Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / 4C.
In no event shall AME Info FZ LLC / 4C be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AMEinfo.com Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
